# FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

> **NCT01413022** · PHASE1 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 44 (estimated)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan
- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **OTHER:** laboratory biomarker analysis
- **OTHER:** flow cytometry
- **OTHER:** immunohistochemistry staining method
- **OTHER:** pharmacological study
- **DRUG:** PF-04136309

## Key facts

- **NCT ID:** NCT01413022
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2013-10
- **Final completion:** 2016-09
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2016-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413022, "FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01413022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*